<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.biopharmawatch.com/news/SPRC/scisparc-nagel-joins-scientific-advisory-board</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:32:00.000Z</news:publication_date>
      <news:title>SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company’s SAB</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-phase-2-renew-trial-ipf-data</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:30:09.000Z</news:publication_date>
      <news:title>Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-third-quarter-2026-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:15:00.000Z</news:publication_date>
      <news:title>Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-q3-2026-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:15:00.000Z</news:publication_date>
      <news:title>MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NGEN/nervgen-third-quarter-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:15:00.000Z</news:publication_date>
      <news:title>NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:05:00.000Z</news:publication_date>
      <news:title>Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IVVD/invivyd-reports-q3-2026-results-and-business-highlights</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:01:00.000Z</news:publication_date>
      <news:title>Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-q3-2026-financial-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:01:00.000Z</news:publication_date>
      <news:title>Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MGTX/meiragtx-oral-presentation-obesityweek-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:31.000Z</news:publication_date>
      <news:title>MeiraGTx Announces Oral Presentation at ObesityWeek 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-jefferies-conference-london</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BRKR/bruker-dr-eicke-latz-board-directors</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Bruker Announces that Institute Director, Biopharma Entrepreneur and Immunology Leader Dr. Eicke Latz will join its Board of Directors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-roche-clinical-trial-collaboration</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-q3-2026-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/XTNT/xtant-medical-q3-2026-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BLRX/biolinerx-hemispherian-glix1-sno-2026-updates</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HELP/helus-pharma-approach-study-hlp003-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-fda-fast-track-onvansertib</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-positive-phase-i-ii-data-lx2020</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TIL/instil-bio-reports-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-opens-new-imaging-centers-november</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>Lumexa Imaging Opens Three New Imaging Centers in November</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GTBP/gt-biopharma-reports-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T12:00:00.000Z</news:publication_date>
      <news:title>GT Biopharma Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDLN/medline-inc-announces-launch-secondary-offering-class-common-stock-20261116</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:53:00.000Z</news:publication_date>
      <news:title>Medline Inc. announces launch of secondary offering of Class A common stock</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDT/medtronic-acquire-contego-medical-carotid-therapies</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:45:00.000Z</news:publication_date>
      <news:title>Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HKPD/cellyan-biotechnology-regains-nasdaq-compliance</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:40:00.000Z</news:publication_date>
      <news:title>CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OSCR/oscar-health-board-expansion-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Oscar Health Expands its Board of Directors with Technology, Healthcare and Product Innovators to Advance Consumer Healthcare</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HSIC/henry-schein-updates-non-gaap-financial-measures</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Henry Schein Updates Presentation of Non-GAAP Financial Measures</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HELP/helus-pharma-q2-fiscal-2027-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AVR/anteris-duravr-thv-one-year-outcomes-pcr-london-valves</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ZYME/zymeworks-share-repurchase-authorization</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Zymeworks Announces $200 Million Share Repurchase Authorization</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KMTS/kestra-ace-pas-wearable-defibrillator-study</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-nulisa-data-ctad-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T11:00:00.000Z</news:publication_date>
      <news:title>Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VANI/vivani-medical-private-placement-financing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T10:30:00.000Z</news:publication_date>
      <news:title>Vivani Medical Announces Private Placement Equity Financing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CYTK/cytokinetics-myqorzo-prescribing-information-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T09:00:00.000Z</news:publication_date>
      <news:title>Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ACRS/aclaris-phase-2b-trial-modzatinib-lichen-planus</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T08:30:00.000Z</news:publication_date>
      <news:title>Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ACRS/aclaris-phase-2-results-bosakitug-atopic-dermatitis</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T08:28:00.000Z</news:publication_date>
      <news:title>Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-11-16</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T07:15:54.444Z</news:publication_date>
      <news:title>Troculeucel Phase 1: Biotech Catalysts Nov 16, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T07:00:00.000Z</news:publication_date>
      <news:title>Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OCS/oculis-fda-ind-clearance-privosegtor-ms-relapses</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T07:00:00.000Z</news:publication_date>
      <news:title>Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EVO/evotec-secures-grant-drug-safety-testing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T06:57:00.000Z</news:publication_date>
      <news:title>Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LKFT/lakefront-new-share-repurchase-program</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T06:30:00.000Z</news:publication_date>
      <news:title>Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HCM/hutchmed-expanded-coverage-nrdl-elunate-orpathys</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T04:00:00.000Z</news:publication_date>
      <news:title>HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-lisaftoclax-olverembatinib-nrdl-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T23:30:00.000Z</news:publication_date>
      <news:title>Ascentage Pharma Announces Inclusion of Lisaftoclax in China&apos;s 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MESO/mesoblast-asx-investor-day-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T23:16:00.000Z</news:publication_date>
      <news:title>Mesoblast Showcased at ASX Premier Investor Day Event</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-nominates-ide101-candidate</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T20:00:00.000Z</news:publication_date>
      <news:title>IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DRTS/alpha-dart-recurrent-glioblastoma-trial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T18:00:00.000Z</news:publication_date>
      <news:title>New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events – Conference Call Scheduled for 8:30am ET November 16</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-vk2735-obesity-week-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T17:05:00.000Z</news:publication_date>
      <news:title>Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HELP/helus-pharma-phase-3-approach-study-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T17:00:00.000Z</news:publication_date>
      <news:title>Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CVS/cvs-health-glp-1-benefits-affordability-challenge</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T15:00:00.000Z</news:publication_date>
      <news:title>CVS Health study highlights GLP-1 benefits and the affordability challenge</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-q3-2026-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:00:00.000Z</news:publication_date>
      <news:title>Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-ivonescimab-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:00:00.000Z</news:publication_date>
      <news:title>Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/COCP/cocrystal-pharma-business-update-q3-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-15T12:00:00.000Z</news:publication_date>
      <news:title>Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LLY/lilly-obesityweek-2026-data-presentation</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-14T17:01:00.000Z</news:publication_date>
      <news:title>Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AMLX/amylyx-avexitide-phase-3-results-obesityweek-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-14T17:00:00.000Z</news:publication_date>
      <news:title>Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/WWB/windward-bio-nasdaq-ipo</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-14T15:57:00.000Z</news:publication_date>
      <news:title>Innovative Immunology Biotech Windward Bio Lists on Nasdaq</news:title>
    </news:news>
  </url>
</urlset>